Regen Medicine Drives Big Uptick In 2015 Start-Up Dealmaking
This article was originally published in Start Up
Executive Summary
Biotech start-ups cut deals at a rapid pace in 2015, signing almost twice the number of alliances done in 2014. Regenerative medicine was prominent in key partnerships.
You may also be interested in...
Gene Therapy: Cures Within Reach
After rocky beginnings, there is increasing optimism about the potential for gene therapy to make an impact in rare disease. Promising data from late-stage clinical trials, improved safety, and the first Western regulatory approval of a gene therapy are now driving numerous initial public offerings, venture capital financings, and tie-ups with major pharmaceutical companies.
“Build-To-Buy” Startup Model Alive And Kicking, Invested Execs Say
VCs and big pharma execs, speaking at CALBIO, said that even in today’s freer economic climate, investing early in startups, with an option to buy when the time is right, is still a viable business strategy.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.